Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NPCE NYSE:NSPR NASDAQ:RXST NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNPCENeuroPace$8.92+0.3%$10.41$5.45▼$18.98$291.58M1.89204,656 shs152,011 shsNSPRInspireMD$2.39-4.4%$2.42$1.99▼$3.80$73.22M0.6103,653 shs56,922 shsRXSTRxSight$7.79+3.2%$11.25$6.32▼$58.23$306.81M1.161.35 million shs1.20 million shsSNWVSanuwave Health$34.32-2.6%$33.23$5.21▼$39.83$301.90M1.2948,998 shs30,670 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNPCENeuroPace+0.34%+4.82%-13.90%-30.80%+34.14%NSPRInspireMD-4.40%-14.34%+5.75%-8.08%-16.43%RXSTRxSight+3.18%+0.13%-39.09%-40.67%-83.15%SNWVSanuwave Health-2.58%-10.79%-1.63%+14.02%+3,431,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNPCENeuroPace2.7109 of 5 stars3.53.00.00.00.04.20.6NSPRInspireMD3.6248 of 5 stars3.53.00.00.03.84.20.6RXSTRxSight3.2856 of 5 stars4.04.00.00.02.31.70.6SNWVSanuwave Health2.2902 of 5 stars3.50.00.00.02.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNPCENeuroPace 3.00Buy$17.0090.58% UpsideNSPRInspireMD 3.00Buy$4.5088.28% UpsideRXSTRxSight 1.91Reduce$12.2256.90% UpsideSNWVSanuwave Health 3.00Buy$49.0042.77% UpsideCurrent Analyst Ratings BreakdownLatest NSPR, RXST, SNWV, and NPCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$49.007/15/2025RXSTRxSightMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.007/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.007/9/2025RXSTRxSightOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.007/9/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.007/9/2025RXSTRxSightBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNPCENeuroPace$84.31M3.47N/AN/A$0.27 per share33.04NSPRInspireMD$7.03M10.42N/AN/A$1.83 per share1.31RXSTRxSight$148.31M2.13N/AN/A$6.98 per share1.12SNWVSanuwave Health$36.19M8.13N/AN/A($1.49) per share-23.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ARXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%N/ASNWVSanuwave Health-$31.37M-$4.56N/A∞N/A-89.86%N/A-145.76%N/ALatest NSPR, RXST, SNWV, and NPCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/7/2025Guidance UpdateRXSTRxSight-$0.0363-$0.29-$0.2537-$0.29$39.78 million$33.64 million5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/9/2025Q1 2025SNWVSanuwave HealthN/A-$0.66N/A-$0.66N/A$9.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNPCENeuroPaceN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNPCENeuroPace2.466.635.70NSPRInspireMDN/A6.396.05RXSTRxSightN/A12.6811.65SNWVSanuwave HealthN/A0.400.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNPCENeuroPace78.83%NSPRInspireMD44.78%RXSTRxSight78.78%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipNPCENeuroPace20.50%NSPRInspireMD34.06%RXSTRxSight9.57%SNWVSanuwave Health14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNPCENeuroPace17032.80 million26.08 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableSNWVSanuwave Health408.57 million7.29 millionN/ANSPR, RXST, SNWV, and NPCE HeadlinesRecent News About These CompaniesSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial ResultsAugust 4, 2025 | globenewswire.comBrokers Issue Forecasts for Sanuwave Health Q2 EarningsAugust 1, 2025 | marketbeat.comRoth Capital Begins Coverage on Sanuwave Health (NASDAQ:SNWV)July 30, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Now Covered by Analysts at Roth CapitalJuly 30, 2025 | americanbankingnews.comSanuwave Health to Present at Canaccord Genuity Growth ConferenceJuly 22, 2025 | globenewswire.comSanuwave: High Growth Wound Care Tech Primed For A BreakoutJune 11, 2025 | seekingalpha.comSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsJune 3, 2025 | globenewswire.comSANUWAVE Health, Inc. (SNWV): A Bull Case TheoryMay 29, 2025 | insidermonkey.comSanuwave Health Appoints Greg Bazar to Board of DirectorsMay 28, 2025 | globenewswire.comSanuwave Health Selected for Inclusion in Russell 2000® IndexMay 28, 2025 | globenewswire.comInsider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of StockMay 17, 2025 | insidertrades.comSANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSanuwave Announces Q1 FY2025 Financial ResultsMay 9, 2025 | globenewswire.comSanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsMay 5, 2025 | globenewswire.comSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)April 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPR, RXST, SNWV, and NPCE Company DescriptionsNeuroPace NASDAQ:NPCE$8.92 +0.03 (+0.34%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$8.74 -0.18 (-1.96%) As of 08/7/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.InspireMD NYSE:NSPR$2.39 -0.11 (-4.40%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.46 +0.07 (+2.93%) As of 08/7/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.RxSight NASDAQ:RXST$7.79 +0.24 (+3.18%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$7.62 -0.17 (-2.18%) As of 08/7/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Sanuwave Health NASDAQ:SNWV$34.32 -0.91 (-2.58%) As of 08/7/2025 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
